Next Article in Journal
A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile
Next Article in Special Issue
Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China
Previous Article in Journal
Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview
Previous Article in Special Issue
Incidence of Guillain-Barré Syndrome Is Not Associated with Influenza Vaccination in the Elderly
Article

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

1
Section of Pediatrics, Department of Health Sciences, University of Florence, Viale Pieraccini 24, 50139 Florence, Italy
2
Immunology and Molecular Microbiology Unit, Meyer Children’s Hospital, Viale Pieraccini 24, 50139 Florence Italy
3
Section of Pediatrics, Department of Neurofarba, University of Florence, Viale Pieraccini 24, 50139 Florence, Italy
4
Prevention Department, Veneto Regional Health Authority, via Don Tosatto 147, 30174 Venice Mestre, Italy
5
Department of Cardiac Thoracic Vascular Sciences and Public Health, Public Health Section, University of Padua, via Leonardo Loredan 18, 35131 Padua, Italy
*
Authors to whom correspondence should be addressed.
Vaccines 2020, 8(3), 469; https://doi.org/10.3390/vaccines8030469
Received: 22 July 2020 / Revised: 18 August 2020 / Accepted: 20 August 2020 / Published: 22 August 2020
Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs. 7, 9, 15 months in Veneto) through an observational retrospective study. Methods: Vaccination started in 2014 in Tuscany and in 2015 in Veneto; the data collected referred to the period 2006–2018 for Tuscany and 2007–2018 for Veneto. Cases of invasive meningococcal disease due to N. Meningitidis B were identified by culture and/or real-time PCR. Results: In Tuscany, pre-vaccine incidence was 1.96 (95% CL 1.52; 2.40) and dropped to 0.62 (95% CL 0.60; 0.64) in the post-4CMenB era. Evaluating only vaccinated children, post-4CMenB incidence was 0.12 (95% CL 0.08; 0.15). In Veneto pre-vaccine incidence was 1.94 (95% CL 1.92; 1.96) and dropped to 1.34 (95% CL 1.31; 1.38) in the post-4CMenB era. In the vaccinated population, MenB incidence was 0.53 (95% CL 0.50; 0.56). Vaccine effectiveness was 93.6% (95% CL 55.4; 99.1) in Tuscany and 91.0% (95% CL 59.9; 97.9) in Veneto, with mean vaccine coverages of 83.9% and 81.7%, respectively. The overall impact (evaluating both vaccinated and unvaccinated children) was 0.68 (95% CL 0.10; 0.89) in Tuscany and 0.31 (95% CL −0.56; 0.69) in Veneto; the total impact (evaluating only vaccinated children) was 0.94 (95% CL 0.56; 0.99) and 0.90 (95% CL 0.57; 0.97), respectively. The relative case reduction (RCR) was 65% in Tuscany and 31% in Veneto. Considering the vaccinated population, the RCR was equal to 91% and 80%, respectively. Conclusion: In conclusion, 4CMenB appears to have a very high effectiveness in Italy; the impact of vaccination appears greater where the immunization program is started early. View Full-Text
Keywords: meningococcus B; vaccination schedule; children; vaccine effectiveness; vaccine impact meningococcus B; vaccination schedule; children; vaccine effectiveness; vaccine impact
Show Figures

Figure 1

MDPI and ACS Style

Azzari, C.; Moriondo, M.; Nieddu, F.; Guarnieri, V.; Lodi, L.; Canessa, C.; Indolfi, G.; Giovannini, M.; Napoletano, G.; Russo, F.; Baldovin, T.; Cocchio, S.; Ricci, S.; Baldo, V. Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018). Vaccines 2020, 8, 469. https://doi.org/10.3390/vaccines8030469

AMA Style

Azzari C, Moriondo M, Nieddu F, Guarnieri V, Lodi L, Canessa C, Indolfi G, Giovannini M, Napoletano G, Russo F, Baldovin T, Cocchio S, Ricci S, Baldo V. Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018). Vaccines. 2020; 8(3):469. https://doi.org/10.3390/vaccines8030469

Chicago/Turabian Style

Azzari, Chiara, Maria Moriondo, Francesco Nieddu, Valentina Guarnieri, Lorenzo Lodi, Clementina Canessa, Giuseppe Indolfi, Mattia Giovannini, Giuseppina Napoletano, Francesca Russo, Tatjana Baldovin, Silvia Cocchio, Silvia Ricci, and Vincenzo Baldo. 2020. "Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)" Vaccines 8, no. 3: 469. https://doi.org/10.3390/vaccines8030469

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop